New Phase III Trial Results for Rivaroxaban
- Details
- Category: Bayer
Findings from three phase III clinical trials will be presented in the plenary session and during oral presentations at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, from December 8 to 11, 2007. The studies evaluated rivaroxaban in head-to-head comparison with enoxaparin, the current standard of care, for the prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery.
Novo Nordisk launches Changing Diabetes Barometer
- Details
- Category: Novo Nordisk
At a media roundtable in Brussels, Novo Nordisk presented the Changing Diabetes Barometer, which will measure and share the worldwide progress in the fight against diabetes on an annual basis. The Barometer is a tool that will provide healthcare professionals, patient organisations, politicians, institutions and media with valuable information on how to improve the quality of diabetes care, bring down diabetes-related complications, extend patients' life expectancy and reduce costs.
Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
- Details
- Category: Pfizer
Pfizer announced that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin calcium) Tablets 80 mg had stabilization or improvement in kidney function. These results were demonstrated in patients with or without chronic kidney disease, metabolic syndrome or type 2 diabetes. This post-hoc analysis of the landmark Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) study, was presented at the Annual Scientific Sessions of the American Heart Association.
Bayer Temporarily Suspends Global Trasylol® Marketing
- Details
- Category: Bayer
Following consultation with the German Federal Institute for Drugs and Medical Devices (BfArM), the U.S. Food and Drug Administration (FDA), Health Canada, and other health authorities, Bayer announced today that it has elected to temporarily suspend worldwide marketing of Trasylol® (aprotinin injection) until final results from the Canadian BART trial can be compiled, received and evaluated.
Novo Nordisk celebrates 75-year commitment to diabetes research
- Details
- Category: Novo Nordisk
Novo Nordisk celebrates two milestone anniversaries, which demonstrates the company's long-term commitment to diabetes care and research. The day marks the 75-year anniversary of the Steno Diabetes Center and the 50-year anniversary of the Hagedorn Research Institute.
Taisho and Pfizer Sign a Letter of Intent for Taishoâs Schizophrenia Drug Candidate
- Details
- Category: Pfizer
Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) and Pfizer Inc. [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) have concluded a letter of intent with regard to TS-032, a new schizophrenia drug candidate discovered by Taisho and currently in the pre-clinical stage. The letter of intent relates to a proposed license agreement regarding rights for development and commercialization of the substance outside Japan.
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients
- Details
- Category: Novartis
Tasigna® (nilotinib) has been approved in the US as a new anti-cancer therapy for certain patients with a life-threatening form of leukemia who are resistant or intolerant to prior treatment including Glivec® (imatinib)*, an established treatment standard and a leading Novartis medicine.
More Pharma News ...
- Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension
- Nexavar® Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
- Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc.
- Pfizer to Appeal German Court Decision in Lipitor Patent Case
- GSK reports third quarter EPS of 23.7p
- Bristol-Myers Squibb Company Reports Financial Results
- Bayer Issues Additional Guidance to Physicians on Trasylol®